- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-TNF13/ APRIL/ TNFSF13 functional antibody
Anti-TNF13/ APRIL/ TNFSF13 functional antibody for cell culture, ELISA & in-vivo assay
Go to APRIL/TNFSF13 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T14676-Ab-1/ GM-Tg-hg-T14676-Ab-2 | Anti-Human APRIL/TNFSF13 monoclonal antibody | Human |
| GM-Tg-rg-T14676-Ab-1/ GM-Tg-rg-T14676-Ab-2 | Anti-Rat APRIL/TNFSF13 monoclonal antibody | Rat |
| GM-Tg-mg-T14676-Ab-1/ GM-Tg-mg-T14676-Ab-2 | Anti-Mouse APRIL/TNFSF13 monoclonal antibody | Mouse |
| GM-Tg-cynog-T14676-Ab-1/ GM-Tg-cynog-T14676-Ab-2 | Anti-Cynomolgus/ Rhesus macaque APRIL/TNFSF13 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T14676-Ab-1/ GM-Tg-felg-T14676-Ab-2 | Anti-Feline APRIL/TNFSF13 monoclonal antibody | Feline |
| GM-Tg-cang-T14676-Ab-1/ GM-Tg-cang-T14676-Ab-2 | Anti-Canine APRIL/TNFSF13 monoclonal antibody | Canine |
| GM-Tg-bovg-T14676-Ab-1/ GM-Tg-bovg-T14676-Ab-2 | Anti-Bovine APRIL/TNFSF13 monoclonal antibody | Bovine |
| GM-Tg-equg-T14676-Ab-1/ GM-Tg-equg-T14676-Ab-2 | Anti-Equine APRIL/TNFSF13 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T14676-Ab-1/ GM-Tg-hg-T14676-Ab-2; GM-Tg-rg-T14676-Ab-1/ GM-Tg-rg-T14676-Ab-2; GM-Tg-mg-T14676-Ab-1/ GM-Tg-mg-T14676-Ab-2; GM-Tg-cynog-T14676-Ab-1/ GM-Tg-cynog-T14676-Ab-2; GM-Tg-felg-T14676-Ab-1/ GM-Tg-felg-T14676-Ab-2; GM-Tg-cang-T14676-Ab-1/ GM-Tg-cang-T14676-Ab-2; GM-Tg-bovg-T14676-Ab-1/ GM-Tg-bovg-T14676-Ab-2; GM-Tg-equg-T14676-Ab-1/ GM-Tg-equg-T14676-Ab-2 |
| Products Name | Anti-APRIL/TNFSF13 monoclonal antibody |
| Format | mab |
| Target Name | APRIL |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-APRIL benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Biosimilar | GMP-Bios-ab-518 | Pre-Made Sibeprenlimab biosimilar, Whole mAb, Anti-TNFSF13/APRIL Antibody: Anti-CD256/TALL-2/TALL2/TNLG7B/TRDL-1/UNQ383/PRO715/ZTNF2 therapeutic antibody |
| Biosimilar | GMP-Bios-INN-742 | Pre-Made Atacicept Biosimilar, Fusion Protein targeting TNFSF13/APRIL fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD256/TALL-2/TALL2/TNLG7B/TRDL-1/UNQ383/PRO715/ZTNF2 |
| Target Antigen | GM-Tg-g-T14676-Ag-1 | Recombinant multi-species TNF13/ APRIL/ TNFSF13 protein |
| Cytokine | GM-Tg-g-T14676-Ag-1 | tumor necrosis factor (ligand) superfamily, member 13 (TNFSF13) protein |
| ORF Viral Vector | pGMLP005046 | human TNFSF13 Lentivirus plasmid |
| ORF Viral Vector | vGMLP005046 | human TNFSF13 Lentivirus particle |
| ORF Viral Vector | pGMLPm003474 | mouse Tnfsf13 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm003474 | mouse Tnfsf13 Lentivirus particle |
Target information
| Target ID | GM-T14676 |
| Target Name | APRIL |
| Gene ID | 8741,69583,287437,100551507,100568281,100328582,538567,100147233 |
| Gene Symbol and Synonyms | 2310026N09Rik,APRIL,CD256,TALL-2,TALL2,TNFSF13,TNLG7B,TRDL-1,Trdl1,UNQ383/PRO715,ZTNF2 |
| Uniprot Accession | O75888 |
| Uniprot Entry Name | TNF13_HUMAN |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | Therapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target |
| Disease | Lupus Glomerulonephritis |
| Gene Ensembl | ENSG00000161955 |
| Target Classification | Checkpoint-Immuno Oncology |
The target: APRIL, gene name: TNFSF13, also named as APRIL, CD256, TALL-2, TALL2, TNLG7B, TRDL-1, UNQ383/PRO715, ZTNF2. The protein encoded by this gene is a member of the tumor necrosis factor (TNF) ligand family. This protein is a ligand for TNFRSF17/BCMA, a member of the TNF receptor family. This protein and its receptor are both found to be important for B cell development. In vitro experiments suggested that this protein may be able to induce apoptosis through its interaction with other TNF receptor family proteins such as TNFRSF6/FAS and TNFRSF14/HVEM. Alternative splicing results in multiple transcript variants. Some transcripts that skip the last exon of the upstream gene (TNFSF12) and continue into the second exon of this gene have been identified; such read-through transcripts are contained in GeneID 407977, TNFSF12-TNFSF13. [provided by RefSeq, Oct 2010].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
